Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets
Metabolomics is an emerging and powerful bioanalytical method supporting clinical investigations. Serum and plasma are commonly used without rational prioritization. Serum is collected after blood coagulation, a complex biochemical process involving active platelet metabolism. This may affect the metabolome and increase the variance, as platelet counts and function may vary substantially in individuals. A multiomics approach systematically investigating the suitability of serum and plasma for clinical studies demonstrated that metabolites correlated well (n = 461, R2 = 0.991), whereas lipid mediators (n = 83, R2 = 0.906) and proteins (n = 322, R2 = 0.860) differed substantially between specimen. Independently, analysis of platelet releasates identified most biomolecules significantly enriched in serum compared to plasma. A prospective, randomized, controlled parallel group metabolomics trial with acetylsalicylic acid administered for 7 days demonstrated that the apparent drug effects significantly differ depending on the analyzed specimen. Only serum analyses of healthy individuals suggested a significant downregulation of TXB2 and 12-HETE, which were specifically formed during coagulation in vitro. Plasma analyses reliably identified acetylsalicylic acid effects on metabolites and lipids occurring in vivo such as an increase in serotonin, 15-deoxy-PGJ2 and sphingosine-1-phosphate and a decrease in polyunsaturated fatty acids. The present data suggest that plasma should be preferred above serum for clinical metabolomics studies as the serum metabolome may be substantially confounded by platelets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of proteome research - (2024) vom: 23. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hagn, Gerhard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetylsalicylic acid |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1021/acs.jproteome.3c00761 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370102398 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370102398 | ||
| 003 | DE-627 | ||
| 005 | 20240324235412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jproteome.3c00761 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370102398 | ||
| 035 | |a (NLM)38520676 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hagn, Gerhard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Metabolomics is an emerging and powerful bioanalytical method supporting clinical investigations. Serum and plasma are commonly used without rational prioritization. Serum is collected after blood coagulation, a complex biochemical process involving active platelet metabolism. This may affect the metabolome and increase the variance, as platelet counts and function may vary substantially in individuals. A multiomics approach systematically investigating the suitability of serum and plasma for clinical studies demonstrated that metabolites correlated well (n = 461, R2 = 0.991), whereas lipid mediators (n = 83, R2 = 0.906) and proteins (n = 322, R2 = 0.860) differed substantially between specimen. Independently, analysis of platelet releasates identified most biomolecules significantly enriched in serum compared to plasma. A prospective, randomized, controlled parallel group metabolomics trial with acetylsalicylic acid administered for 7 days demonstrated that the apparent drug effects significantly differ depending on the analyzed specimen. Only serum analyses of healthy individuals suggested a significant downregulation of TXB2 and 12-HETE, which were specifically formed during coagulation in vitro. Plasma analyses reliably identified acetylsalicylic acid effects on metabolites and lipids occurring in vivo such as an increase in serotonin, 15-deoxy-PGJ2 and sphingosine-1-phosphate and a decrease in polyunsaturated fatty acids. The present data suggest that plasma should be preferred above serum for clinical metabolomics studies as the serum metabolome may be substantially confounded by platelets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acetylsalicylic acid | |
| 650 | 4 | |a clinical metabolomics | |
| 650 | 4 | |a confounders | |
| 650 | 4 | |a drug effects | |
| 650 | 4 | |a lipid mediators | |
| 650 | 4 | |a metabolomics | |
| 650 | 4 | |a omega-3 fatty acids | |
| 650 | 4 | |a plasma | |
| 650 | 4 | |a platelets | |
| 650 | 4 | |a serum | |
| 700 | 1 | |a Meier-Menches, Samuel M |e verfasserin |4 aut | |
| 700 | 1 | |a Plessl-Walder, Günter |e verfasserin |4 aut | |
| 700 | 1 | |a Mitra, Gaurav |e verfasserin |4 aut | |
| 700 | 1 | |a Mohr, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Preindl, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Schlatter, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidl, Doreen |e verfasserin |4 aut | |
| 700 | 1 | |a Gerner, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Garhöfer, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Bileck, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of proteome research |d 2002 |g (2024) vom: 23. März |w (DE-627)NLM124173470 |x 1535-3907 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jproteome.3c00761 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 03 | ||